Drug-eluting or bare-metal stents for coronary artery disease

New England Journal of Medicine

Volumn 375, Issue 13, 2016, Pages 1242-1252

  Bonaa K H ^a,d,f   Mannsverk, J ^c   Wiseth, R ^e,f   Aaberge, L ^a   Myreng, Y ⁱ   Nygard O ^j,k   Nilsen, D W ^k,l   Klow N E ^a,h   Uchto, M ^m   Trovik, T ^c   Bendz, B ^a,h   Stavnes, S ⁱ   Bjornerheim R ^g   Larsen, A I ^k,l   Slette, M ^f   Steigen, T ^b,c   Jakobsen, O J ^m   Bleie, O ^j   Fossum, E ^a   Hanssen, T A ^b,c   Dahl Eriksen, O ^c   Njolstad I ^a   Rasmussen, K ^b,c   Wilsgaard, T ^a   Nordrehaug, J E ^k,l   more..

^a Department of Community Medicine ^*  (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d Departments of Public Health and General Medicine   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ Feiring Heart Clinic   (Norway)

^j HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^k UNIVERSITY OF BERGEN   (Norway)

^l STAVANGER UNIVERSITY HOSPITAL   (Norway)

^m Sørlandet Hospital   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT OUTCOME; ZOTAROLIMUS ELUTING CORONARY STENT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; RETREATMENT; STATISTICS AND NUMERICAL DATA; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

EVEROLIMUS; RAPAMYCIN; ZOTAROLIMUS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RETREATMENT; SIROLIMUS; STENTS;

EID: 84990028154     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1607991     Document Type: Article

References (21)

1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65.
2. Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med 2011; 364: 453-64.
3. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784-814.
4. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55.
5. Jensen LO, Thayssen P, Christiansen EH, et al. Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV. J Am Coll Car-diol 2016;67:751-62.
6. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and reste-nosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiog-raphy and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33: 606-13.
7. Sabaté M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90.
8. Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarc-tion treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet 2016; 387: 357-66.
9. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402.
10. Bhatt DL. EXAMINATION of new drug-eluting stents-top of the class! Lancet 2012;380:1453-5.
11. Alfonso F, Fernandez C. Second-generation drug-eluting stents. Moving the field forward. J Am Coll Cardiol 2011; 58: 26-9.
12. Räber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-21.
13. Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010;363:2310-9.
14. Bangalore S, Kumar S, Fusaro M, et al. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125: 2873-91.
15. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial in-farction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013;62:496-504.
16. Venkitachalam L, Lei Y, Magnuson EA, et al. Survival benefit with drug-elut-ing stents in observational studies: fact or artifact? Circ Cardiovasc Qual Outcomes 2011;4:587-94.
17. Stone GW, Pocock SJ. Randomized trials, statistics, and clinical inference. J Am Coll Cardiol 2010; 55: 428-31.
18. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
19. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-47.
20. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new func-tional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25: 333-41.
21. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008; 359: 677-87.